title: The utility of tetraspanin CD9 as a biomarker for metastatic clear cell renal cell carcinoma.
abstract: The use of tetraspanin CD9 as a biomarker for renal cell carcinomas (RCC) has been explored with minor conclusions. Identification of a biomarker that not only distinguishes between the different types of renal cell carcinomas, but also predicts the metastatic potential of these tumors would significantly advance diagnosis and prognosis of kidney cancers. We utilized established cell lines to better understand the contribution of CD9 to the metastatic potential of clear cell renal cell carcinomas, and then applied our findings to the TCGA database and immunohistochemical analysis of human samples based on tumor grading to determine the utility of CD9 as a biomarker for RCC. Clear cell renal cell carcinoma (ccRCC) cell expression of tetraspanin CD9 was compared to normal kidney cells and found to be elevated. Upon knockdown of CD9, ccRCC cells obtained a more metastatic phenotype. We found E-cadherin expression to be repressed and the endothelial to mesenchymal transition markers Snail, Twist1, and Zeb1 to be elevated upon CD9 knockdown. Upon observing these gene expression changes in the TCGA database and in 10 cases, we found that CD9 and E-cadherin expression was lowered in higher grade ccRCC tumors. There was a significant correlation between CD9 and either E-cadherin, Snail, or Zeb1 in these tumors. Collectively, using tetraspanin CD9 in tandem with E-cadherin as a biomarker in renal cell carcinoma will help to not only distinguish between types, but also predict the metastatic potential of RCC.
authors: The University of Tennessee Health Science Center, Memphis, TN, USA.
authors: Jo M
authors: JM
authors: Garner
authors: The University of Tennessee Health Science Center, Memphis, TN, USA; CirQuest Labs, LLC, Memphis, TN, USA. Electronic address: michaelherr@cirquestlabs.com.
authors: Michael J
authors: MJ
authors: Herr
authors: The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors: Kurt B
authors: KB
authors: Hodges
authors: The University of Tennessee Health Science Center, Memphis, TN, USA; CirQuest Labs, LLC, Memphis, TN, USA.
authors: Lisa K
authors: LK
authors: Jennings
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism; D015820:Cadherins / Q000378:metabolism*; D002292:Carcinoma, Renal Cell / Q000175:diagnosis / Q000378:metabolism* / Q000556:secondary*; D045744:Cell Line, Tumor / Q000378:metabolism*; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000175:diagnosis / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D060245:Tetraspanin 29 / Q000378:metabolism*
chemical_list: D014408:Biomarkers, Tumor; C554869:CD9 protein, human; D015820:Cadherins; D060245:Tetraspanin 29
keywords: Biomarker; Clear cell renal cell carcinoma; E-cadherin; Metastasis; Tetraspanin CD9